Capricor Therapeutics (CAPR) Revenue (2011 - 2024)

Capricor Therapeutics' Revenue history runs 14 years deep, the most recent figure standing at $11.1 million for Q4 2024.

• In Q4 2024, Revenue fell 7.92% year-over-year to $11.1 million; the TTM figure through Sep 2025 stood at $11.1 million (down 60.7% YoY), while the FY2024 annual figure was $22.3 million, down 11.55% from the prior year.
• Revenue was $11.1 million for Q4 2024 at Capricor Therapeutics, up from $2.3 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $12.1 million in Q4 2023 to a low of $16863.0 in Q3 2020.
• Historically, Revenue has averaged $3.5 million across 5 years, with a median of $1.9 million in 2022.
• The sharpest annual moves came in 2020 and 2023: Revenue plunged 88.13% in 2020, then soared 1159.3% in 2023.
• A 5-year view of Revenue shows it stood at $57830.0 in 2020, then surged by 252.9% to $204082.0 in 2021, then surged by 370.35% to $959903.0 in 2022, then jumped by 1159.3% to $12.1 million in 2023, then slipped by 7.92% to $11.1 million in 2024.
• The last three Revenue figures came in at $11.1 million (Q4 2024), $2.3 million (Q3 2024), and $4.0 million (Q2 2024), per Business Quant data.